Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.45 |
| ▸ | TACR1 | P25103 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946034 | 0.86 | FFAR4 (0.55) | FFAR4FFAR1MRGPRX4 | |
| SCHEMBL12868786 | 0.84 | FFAR4 (0.54) | FFAR4FFAR1MRGPRX4HTTSMN1; SMN2 | |
| SCHEMBL26581173 | 0.81 | IDO1 (0.45) | FFAR4FFAR1MRGPRX4LMNA | |
| SCHEMBL9946103 | 0.79 | FFAR4 (0.40) | FFAR4FFAR1MRGPRX4BCHEACHE | |
| SCHEMBL9946090 | 0.78 | PARP10 (0.55) | FFAR1MRGPRX4ACHEPARP10 | |
| SCHEMBL11449830 | 0.78 | KMT2A (0.48) | BCHEACHELMNAHTTSMN1; SMN2 | |
| SCHEMBL19121473 | 0.76 | ALDH1A1 (0.47) | BCHEACHELMNAHTTSMN1; SMN2 | |
| SCHEMBL17129455 | 0.75 | CCR5 (0.49) | LMNA | |
| SCHEMBL12062743 | 0.75 | LMNA (0.41) | BCHEACHELMNAHTTSMN1; SMN2 | |
| SCHEMBL9945950 | 0.75 | HTT (0.47) | BCHEACHELMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | FFAR4 1371/4885FFAR1 1083/4885MRGPRX4 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.